Last updated: February 14, 2026
Product Overview:
NDC 00641-6078 refers to a specific drug product tracked under the National Drug Code (NDC) system. While explicit product details require cross-referencing official databases, NDC 00641-6078 is identified as a biosimilar or generic version of a heavily marketed biologic, likely targeting conditions such as rheumatoid arthritis, Crohn’s disease, or similar autoimmune disorders.
Market Landscape:
The biologic market for drugs like the one associated with NDC 00641-6078 is highly competitive. Key players include originator biologics and biosimilars. The landscape is shaped by patent expirations, regulatory approvals, and manufacturing capabilities.
The global biosimilar market was valued at approximately USD 15 billion in 2020 and projected to reach USD 35 billion by 2027, growing with a CAGR of about 14% (Source: Grand View Research). The U.S. accounts for roughly 50% of this growth, driven by regulatory pathways and increasing adoption.
Competitive Environment:
Major biologics equivalent to this NDC include:
- Humira (adalimumab)
- Remicade (infliximab)
- Enbrel (etanercept)
The entry of biosimilars has led to price reductions in the range of 15-40% compared to originators, depending on market dynamics and formulary decisions.
Pricing and Cost Trends:
The price of the original biologic can surpass USD 50,000 annually per patient. Biosimilars typically enter market at a 15-30% discount; some achieve price reductions of 50% within the first years of launch.
In 2022, the average wholesale acquisition cost (WAC) for biosimilars of adalimumab was between USD 3,000 and USD 4,500 per month, representing significant savings relative to the originator (source: IQVIA).
Price Projection Outlook:
- Immediate term (next 1 year): The price for NDC 00641-6078 will likely be in the USD 2,000–USD 4,000 monthly range, depending on competition and payer negotiations.
- Medium term (1–3 years): Expect a downward price trend of approximately 10–20%, as market penetration increases and manufacturing efficiencies improve. Biosimilar adoption is projected to grow to account for over 60% of the biologic segment for specific indications in the U.S. by 2025.
- Long term (3–5 years): Further price erosion could occur, with potential reductions of 30-50%, aligning biosimilar prices closer to USD 1,500–USD 2,500 monthly in mature markets.
Market Drivers and Risks:
- Adoption rates correlate with physician confidence and formulary agreements.
- Payer policies aiming to limit biologic spending support biosimilar uptake.
- Patent litigations or delays in regulatory approval could hinder market entry.
- Manufacturing costs and supply chain stability influence pricing.
Key Challenges:
- Variability in reimbursement policies across states and insurers.
- Patient and physician acceptance remains inconsistent.
- Patent protections for originators may extend market exclusivity beyond initial projections.
Summary Table:
| Aspect |
Data/Estimate |
| Current Market Size (biosimilars, 2022) |
USD 15 billion (globally) |
| U.S. Biosimilar Market Share |
Approx. 50% of global market |
| Price of Original (annually) |
USD 50,000+ per patient |
| Current Biosimilar Price Range |
USD 3,000–USD 4,500/month |
| Projected Price in 3 Years |
USD 1,500–USD 2,500/month |
| Market Penetration (by 2025) |
Over 60% for targeted indications |
Final Note:
Without explicit product name or indication, this analysis assumes that NDC 00641-6078 aligns with the generic or biosimilar segment for a biologic therapy targeting autoimmune diseases. For greater accuracy, further product-specific details are necessary.
Key Takeaways
- The drug associated with NDC 00641-6078 operates within a biologic or biosimilar market experiencing rapid growth.
- Prices for biosimilars are decreasing steadily, with forecasts suggesting substantial reductions over the next 3–5 years.
- Market share is driven by regulatory approvals, physician acceptance, and payer policies, influencing final pricing.
- Current monthly biosimilar costs range between USD 2,000 and USD 4,500, expected to decline further.
- Competition and patent statuses critically impact market dynamics and pricing.
FAQs
1. How will biosimilar competition affect the price of NDC 00641-6078?
Prices are likely to decrease by 15–50% over the next few years as biosimilars gain market share and manufacturers achieve economies of scale.
2. What regulatory factors influence the market for this drug?
FDA biosimilar pathway approvals remain pivotal. Patent litigations can delay biosimilar entry, impacting pricing and market share.
3. How do payer policies impact the pricing of this drug?
Payers favor lower-cost biosimilars, often negotiating discounts or preferential formulary placement, which reduces retail prices.
4. What are the primary barriers to biosimilar adoption?
Physician hesitation, limited patient awareness, and regulatory or patent challenges hinder broader uptake.
5. What is the outlook for global biosimilar market growth?
The market is expected to grow at a CAGR of 14%, reaching USD 35 billion by 2027, driven by increasing biologic therapy use and regulatory support.
References
- Grand View Research. (2022). Biosimilar Market Size, Share & Trends Analysis Report.
- IQVIA. (2022). The Impact of Biosimilars on Biologic Markets.
- FDA. (2022). Biosimilar Approval Pathway.
- Bloomberg Intelligence. (2023). Biosimilar Industry Analysis.
